Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 28 September 2023, 16:05 HKT/SGT
Share:
    

Source: Eisai
Eisai Launches New "Innovation" Page on Corporate Website

Eisai Co., Ltd. announced today that it has launched a new “Innovation” page on its corporate website. The "Innovation" page is comprised of four sections: "Research & Development (R&D)," "Ecosystem," "Open Innovation," and "Corporate Venture Capital," which are the core of Eisai’s innovation creation. Each part introduces information such as Eisai’s strengths, originality, and the status of specific initiatives.

"Innovation" top page www.eisai.com/innovation/index.html

Eisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept, (also known as our human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities.

On the newly established "Innovation" page, Eisai has enhanced information on policies, characteristics, and examples of initiatives for innovation creation aimed at realizing it’s corporate concept. The “R&D” section contains new contents, such as an overview of the Deep Human Biology Learning (DHBL) drug discovery and development system, which was established last year, track records of Eisai’s long-term commitment to dementia, oncology and tropical diseases, and the current status of digital technology application in R&D settings. In addition, the "Ecosystem" section explains Eisai’s policy of evolving into an hhceco (hhc concept + ecosystem) company to empower people to “realize their fullest lives” how they would like, from the time that they are in good health up to their final moments, and the dementia hhceco model on which Eisai is focusing. Moreover, the “Open Innovation” and “Corporate Venture Capital” sections introduce their respective business policies and achievements, and an inquiry page for new partnering opportunities has been established.

Eisai will continue to disclose information in a proactive and easy-to-understand manner through our corporate website and communicate with all of our stakeholders to help them understand our corporate concept and business activities.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120




Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Feb 21, 2024 14:26 HKT/SGT
Eisai to Boost Initiatives on Greenhouse Gas Reduction, Aiming to Achieve Net Zero by 2050
Feb 20, 2024 08:35 HKT/SGT
Eisai Selected for 'Human Capital Leaders 2023' and 'Human Capital Management Gold Quality', Recognized as Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
Feb 16, 2024 08:31 HKT/SGT
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan
Feb 1, 2024 17:04 HKT/SGT
Eisai Commences Fully-Fledged Business Activities at Pharma Sales Subsidiary in South Africa
Jan 26, 2024 15:26 HKT/SGT
Eisai Submits New Drug Application for Mecobalamin Ultrahigh-Dose Formulation in Japan for the Indication of Amyotrophic Lateral Sclerosis
Jan 18, 2024 14:12 HKT/SGT
Eisai: Antiepileptic Drug Fycompa Injection Formulation Approved in Japan
Jan 17, 2024 16:08 HKT/SGT
Eisai Listed as a Global 100 Most Sustainable Corporation for the Eighth Time
Jan 16, 2024 09:25 HKT/SGT
Eisai Furthers Oncology Research Across Multiple Cancers at ASCO GI and ASCO GU 2024
Jan 11, 2024 15:33 HKT/SGT
Eisai: The Scientific Advisory Group (SAG) to Convene to Discuss the Marketing Authorization Application for lecanemab in the EU
Jan 10, 2024 09:15 HKT/SGT
"> Eisai: "LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in China
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: